![](/images/png/glyphicons-368-expand.png)
![](/images/png/glyphicons-791-one-day.png)
![](/images/png/glyphicons-791-one-day.png)
Uroplasty To Participate In The Oppenheimer 23rd Annual Healthcare Conference
Uroplasty To Participate In The Oppenheimer 23rd Annual Healthcare Conference -- MINNEAPOLIS, Dec. 5, 2012 /PRNewswire/ --
MINNEAPOLIS, Dec. 5, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: [ UPI ]), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced its participation in the Oppenheimer 23rd Annual Healthcare Conference on Thursday, December 13, 2012, at 1:00 p.m. ET at the Waldorf Hotel in New York. Medi Jiwani, Chief Financial Officer, will present and meet with investors one on one at the conference in New York City.
Attendance at the conference is by invitation only. A live audio webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at [ http://www.veracast.com/webcasts/opco/healthcare2012/29210507.cfm ], or through Uroplasty's website at [ www.uroplasty.com ]. An archived replay of the presentation will be available for 90 days.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at [ www.uroplasty.com ].
For Further Information: Uroplasty, Inc. David Kaysen, President and CEO, or Medi Jiwani, Vice President, CFO, Treasurer 952.426.6140 |
EVC Group Doug Sherk/Jenifer Kirtland (Investors), Chris Gale (Media), 646.201.5431 |
SOURCE Uroplasty, Inc.
RELATED LINKS
[ http://www.uroplasty.com ]